Aaron Y. Mochizuki, DO
- Pediatric Neuro-Oncologist, Division of Oncology
- Assistant Professor, UC Department of Pediatrics
- aaron.mochizuki@cchmc.org
- Board Certified
About
Biography
As a pediatric neuro-oncologist, I treat patients with brain tumors as well as other solid tumors. I seek to provide compassionate care to each person and their family.
The awe-inspiring children going through the most challenging circumstances and their incredible families who support them inspired me to pursue my career.
My research examines how brain tumor immune-cell populations change with therapy and how those changes can predict treatment response.
In my free time, I enjoy running, hiking and snowboarding.
Medical School: A.T. Still University, Mesa, AZ, 2013.
Internship: University of Hawaii, Honolulu, HI, 2014.
Residency: LAC+USC Medical Center, Los Angeles, CA, 2016.
Fellowship: Pediatric Hematology/Oncology, UCLA, Los Angeles, CA, 2019.
Fellowship: Pediatric Neuro-Oncology, Stanford University, Palo Alto, CA, 2021.
Board Certifications: General Pediatrics, 2016; Pediatric Hematology/Oncology, 2021.
Interests
Pediatric neuro-oncology; immunotherapy
Services and Specialties
Brain Tumor Center
Interests
Data science; tumor microenvironment
Research Areas
Oncology
Additional Languages
SpanishLocations (2)
Insurance Information
Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.
Publications
14q22.3 duplication including OTX2 in a girl with medulloblastoma: A case report with literature review. American Journal of Medical Genetics, Part A. 2024; 194:e63604.
IMMU-17. A PHASE I STUDY OF INTRATUMORAL/PERITUMORAL HERPES SIMPLEX VIRUS-1 MUTANT HSV1716 IN PATIENTS WITH REFRACTORY OF RECURRENT HIGH-GRADE GLIOMAS: A PEDIATRIC BRAIN TUMOR CONSORTIUM STUDY. Neuro-Oncology. 2024; 26:0.
MDB-45. THE PTBP2 SPLICING FACTOR IS ESSENTIAL IN GROUP 3/4 MEDULLOBLASTOMA. Neuro-Oncology. 2024; 26:0.
Pediatric Embryonal Tumors. Neuro-Oncology Compendium for the Boards and Clinical Practice. : Oxford University Press (OUP); Oxford University Press (OUP); 2023.
CNSC-01. GABAERGIC NEURON-TO-GLIOMA SYNAPSES IN DIFFUSE MIDLINE GLIOMAS. Neuro-Oncology. 2023; 25:i11.
MDB-17. THE PTBP2 SPLICING FACTOR IS ESSENTIAL IN GROUP 3/4 MEDULLOBLASTOMA. Neuro-Oncology. 2023; 25:i65.
GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. Nature. 2022; 603:934-941.
Neoadjuvant PD-1 blockade induces T cell and cDC1 activation but fails to overcome the immunosuppressive tumor associated macrophages in recurrent glioblastoma. Nature Communications. 2021; 12:6938.
A Pilot Study of Low-Dose Craniospinal Irradiation in Patients With Newly Diagnosed Average-Risk Medulloblastoma. Frontiers in Oncology. 2021; 11:744739.
Advanced Age Increases Immunosuppression in the Brain and Decreases Immunotherapeutic Efficacy in Subjects with Glioblastoma. Clinical Cancer Research. 2020; 26:5232-5245.
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026
© 1999-2024 Cincinnati Children's Hospital Medical Center. All rights reserved.
Patient Ratings and Comments
All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent patient satisfaction company, NRC Health. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey